Medizone International, Inc.

Equities

MZEIQ

US5850131054

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-16.67%	+525.00%

2021	Medizone International, Inc. Went Out of Business	CI
2019	Edwin G. Marshall and Jill C. Marshall cancelled the acquisition of substantially all assets of Medizone International, Inc. (OTCPK:MZEI.Q).	CI

Medizone International, Inc. Bankruptcy Case Dismissed

July 16, 2018 at 09:30 am IST

The US Bankruptcy Court dismissed the Chapter 11 involuntary petition filed against Medizone International, Inc. on July 16, 2018. The alleged debtor's chapter 7 case is pending in the Las Vegas division of the Court and therefore no need to run a separate case.

Latest news about Medizone International, Inc.

Medizone International, Inc. Went Out of Business	17/21/17	CI
Edwin G. Marshall and Jill C. Marshall cancelled the acquisition of substantially all assets of Medizone International, Inc. (OTCPK:MZEI.Q).	17/19/17	CI
Edwin G. Marshall and Jill C. Marshall entered into a purchase and sale agreement to acquire substantially all assets of Medizone International, Inc. (OTCPK:MZEI.Q) for $0.5 million.	05/18/05	CI
Motion for Asset Sale Approved for Medizone International, Inc.	10/18/10	CI
Bidding Procedure Approved for Medizone International, Inc.	26/18/26	CI
Medizone International, Inc. Bankruptcy Case Dismissed	16/18/16	CI
Motion for Asset Sale Filed by Medizone International, Inc.	29/18/29	CI
Final DIP Financing Approved for Medizone International, Inc.	15/18/15	CI
Interim DIP Financing Approved for Medizone International, Inc.	01/18/01	CI
Medizone International, Inc. Filed for Bankruptcy	08/18/08	CI
Medizone International and Innovasource Implement & Expand Exclusive AsepticSure® Product Evaluation Agreement	03/18/03	CI
Medizone International, Inc. Announces Resignation of Philip A. Theodore as Executive Vice President Operations and Administration, General Counsel and Corporate Secretary	24/18/24	CI
Involuntary Petition Filed Against Medizone International, Inc.	18/18/18	CI
Medizone International, Inc. Auditor Raises 'Going Concern' Doubt	20/18/20	CI
Medizone International, Inc. announced that it expects to receive $10.29 million in funding from L2 Capital, LLC, Sea Otter Global Ventures LLC	31/18/31	CI
Medizone International, Inc. Names Jude P. Dinges as Executive Vice President - Commercial Operations	31/18/31	CI
Medizone International, Inc. Appoints Philip A. Theodore as Executive Vice President — Operations and Administration, General Counsel and Corporate Secretary	31/17/31	CI
Medizone International, Inc. and Aglon A/S Enters into an Agreement for the Introduction and Distribution of Asepticsure	30/17/30	CI
Medizone International, Inc. announced that it expects to receive $0.06 million in funding	30/17/30	CI
Medizone International, Inc. Announces Management Changes	18/17/18	CI
Dwayne Montgomery to Step Down from Medizone International, Inc. Effective August 31, 2017	23/17/23	CI
Medizone International, Inc. Announces Retirement of Daniel D. Hoyt as Director	23/17/23	CI
Medizone International, Inc. Receives Full Approval of International Electrical Safety Standards for All Models of AsepticSure	21/17/21	CI
Medizone International, Inc. Appoints Brad Goble to Lead Efforts to Engage with Government Agencies and Organizations Tasked with Coordinating Global Resources	30/17/30	CI
Medizone International, Inc. Appoints Steve Meyer to its Board of Directors	22/17/22	CI

Chart Medizone International, Inc.

Duration

Period

More charts

Company Profile

Medizone International, Inc. is engaged in designing, manufacturing and selling a system using ozone in the disinfection of surgical and other medical treatment facilities and in other applications. The Company's AsepticSure is an ozone-based technology, which is used for the purpose of decontaminating and disinfecting hospital surgical suites, emergency rooms, intensive care units and other enclosed spaces, such as gym locker rooms, laboratories and veterinary clinics. In the AsepticSure system, oxygen atoms are misted into the environment with a hydrogen peroxide vapor and the system's formula creates Trioxidane. The Company is developing a variant of AsepticSure for governmental use with bio-terrorism countermeasures. AsepticSure has completed safety and preliminary operational trials. During the tests, AsepticSure has demonstrated a turnaround time of approximately 90 minutes for disinfection and reoccupation of the hospital rooms.

Sector

More about the company